<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458117</url>
  </required_header>
  <id_info>
    <org_study_id>20139157</org_study_id>
    <nct_id>NCT03458117</nct_id>
  </id_info>
  <brief_title>T-VEC in Non-melanoma Skin Cancer</brief_title>
  <acronym>20139157 T-VEC</acronym>
  <official_title>A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with
      locally advanced non-melanoma skin cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the administration of T-VEC in non-melanoma skin cancer. The aim is to
      evaluate the effectiveness, safety and tolerability of T-VEC in patients with non-melanoma
      skin cancer through determination of local immune effects after repeated T-VEC injections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline local immune effects after repeated T-VEC injections</measure>
    <time_frame>at baseline, after 3 injections (week 6) and optionally after 6 injections (week 12)</time_frame>
    <description>Detection of increased local immune activation markers in skin biopsies of injected lesions. The following markers will be assessed by Polymerase chain reaction (PCR): interferon (IFN), 2-prime, 5-prime oligoadenylate synthetase 1 (OAS1), Interferon-induced GTP-binding protein MxA (MXA) and C-X-C motif chemokine 11 (CXCL11)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of Tumor Regression using World Health Organization (WHO) response criteria</measure>
    <time_frame>at baseline and at week 22</time_frame>
    <description>Measurement of the treated tumor size will be performed at baseline and at each visit until end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic immune response</measure>
    <time_frame>at baseline and week 6, optionally also at week 12</time_frame>
    <description>Detection of increased systemic immune Response markers in sera and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Adverse events</measure>
    <time_frame>At week 1, 4, 6, 8, 10, 12, 14, 16, 18, 22</time_frame>
    <description>All serious and non-serious adverse events that occur after enrollment through 30 (+7) days after the last administration of T-VEC will be recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-melanoma Skin Cancer</condition>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Cutaneous Lymphoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Talimogene Laherparepvec (T-VEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Talimogene Laherparepvec (T-VEC)</intervention_name>
    <description>a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)</description>
    <arm_group_label>Talimogene Laherparepvec (T-VEC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects Age ≥ 18 years

          -  histologically confirmed diagnosis of locally advanced squamous cell carcinoma, basal
             cell, carcinoma, Merkel cell carcinoma or cutaneous T cell lymphoma

          -  at least 1 injectable cutaneous lesion ≥ 20 mm in longest Diameter or multiple
             injectable lesions that in Aggregate have a longest Diameter of ≥ 50 mm

          -  Eastern Cooperative Oncology Group-Status (ECOG Status) 0 or 1

          -  Adequate organ functions

        Exclusion Criteria:

          -  Hypersensitivity to T-VEC or any of ist components

          -  Presence of organ and lymph node metastases

          -  history or evidence of active autoimmune disease that requires systemic Treatment

          -  Evidence of clinically significant immunosuppression

          -  active herpetic skin lesions or prior complications hereof

          -  pregnancy, breast feeding

          -  requires intermittent or chronic systemic Treatment with an antiherpetic drug

          -  acute or chronic active Hepatitis B or C infection or HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhard Dummer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>vice-director dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Dummer, Prof. Dr.</last_name>
    <phone>+41 44 255 25 07</phone>
    <email>reinhard.dummer@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuella Guenova-Hötzenecker, PD Dr.</last_name>
    <phone>+41 44 255 25 07</phone>
    <email>emmanuella.guenova@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Dummer, MD</last_name>
      <email>Reinhard.Dummer@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Simone M Goldinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

